Breaking News

What companies are doing to scale up CAR-T production; biotech's Catch-22

 

Pharmalot Ed Silverman

STAT+: Companies can't make CAR-T cells for cancer treatment quickly enough. Here's what they're doing about it

By Angus Chen

Adobe

Unexpected demand for an immunotherapy is worsened by shortages of a component that's also used in Covid vaccines.

Read More

'How do you decide?': Cancer treatment's CAR-T crisis has patients dying on a waitlist

By Angus Chen

MD Anderson Cancer Center

The shortage of CAR-T therapy for multiple myeloma is creating a gut-wrenching dilemma for clinicians — deciding who gets the chance to live.

Read More

Listen: Biotech's Catch-22, a $100 genome, & dealing with monkeypox

By Damian Garde and Meg Tirrell and Adam Feuerstein

Health care strategist Jared Holz of Oppenheimer joins us to discuss what it will take to change Wall Street's dire view of the drug industry.

Read More

How the Covid-19 pandemic prepared the White House to respond to monkeypox

By Rachel Cohrs

Brian Ach/Getty Images for TIME 100 Health Summit

STAT spoke with White House official Raj Panjabi about how lessons from the Covid-19 pandemic are helping with the new monkeypox outbreak.

Read More

Thursday, June 2, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments